UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

~~Form~~ FORM 8-K

~~Current Report~~CURRENT REPORT

~~Pursuant to~~PURSUANT ~~Section~~TO SECTION 13 orOR 15(d) ofOF ~~the Securities Exchange Act of 1934~~THE

~~October~~SECURITIES 8,EXCHANGE ~~2025~~ACT OF 1934

Date of Report (Date of earliest event reported): March 6, 2026

Drugs Made In America Acquisition II Corp.

(Exact Name of Registrant as Specified in ~~its~~ Charter)

Cayman Islands	001-42863	9899-1815624
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1 East Broward Boulevard, Suite 700 Fort Lauderdale, FL		33301
(Address of Principal Executive Offices)		(Zip Code)

1 East Broward Boulevard, Suite 700

~~Registrant’s telephone~~Fort ~~number~~Lauderdale, ~~including~~FL ~~area code: (954) 870-3099~~33301

~~N/A~~(Address of Principal Executive Offices) (Zip Code)

~~(Former name or former address, if changed since last report)~~646-726-7074

~~Check the~~(Registrant’s ~~appropriate~~Telephone ~~box~~Number, ~~below~~Including ~~if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under~~Area ~~any of the following provisions:~~Code)

☐Not Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange ActApplicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one Ordinary Share and one Right to receive one-tenth (1/10) of one Ordinary Share	DMIIU	The Nasdaq Stock Market LLC
Units, each consisting of one ordinary share, $0.0001 par value, and one right to receive one-tenth of one ordinary share	DMIIU	The Nasdaq Stock Market LLC
Ordinary Shares, par value $0.0001 per share	DMII	The Nasdaq Stock Market LLC
Ordinary shares, par value $0.0001 per share	DMII	The Nasdaq Stock Market LLC
Rights, each entitling the holder to receive one-tenth (1/10) of one Ordinary Share	DMIIR	The Nasdaq Stock Market LLC
Rights, each entitling the holder to receive one-tenth of one Ordinary Share	DMIIR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (~~17 CFR~~ §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (~~17 CFR~~ §240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 58.0201. ~~Departure~~Other ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.~~Events

~~Resignation~~As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2026, Drugs Made In America Acquisition II Corp. (the “Company”) announced that, between the completion of ~~Principal~~its ~~Financial~~initial public offering on September 26, 2025 and ~~Accounting~~December 31, ~~Officer~~2025, the sponsor to the Company made certain improper withdrawals (the “Irregularities”) from the Company’s working capital account.

~~On October~~As 8,a ~~2025,~~result ~~Glenn~~of ~~Worman,~~ the ~~Chief~~events reported ~~Financial~~above, ~~Officer~~the ~~and~~board ~~principal~~of ~~financial~~directors ~~and accounting officer~~ of ~~Drugs Made In America Acquisition II Corp. (~~the “Company”) ~~delivered~~immediately totook ~~the~~action ~~Company~~to aconfirm ~~notice~~that ofthe ~~resignation~~Irregularities ~~from~~did ~~his~~not ~~position~~extend asto ~~Chief Financial Officer and principal financial and accounting officer of~~ the Company~~. Mr. Worman~~’s ~~resignation~~trust isaccount ~~effective~~(“Trust ~~October 8~~Account”), ~~2025. Mr. Worman~~and ~~indicated~~as ~~that~~of ~~his~~today, ~~resignation~~March ~~was~~6, ~~not~~2026, the ~~result of any disagreement with the~~ Company ~~regarding~~is ~~its~~confirming ~~operations,~~that ~~policies~~approximately $507,841,957 ~~practices or~~is ~~otherwise~~the Trust Account.

~~Appointment of Principal Financial and Accounting Officer~~1

On November 17, 2025, the Company appointed Saleem Elmasri as Chief Financial Officer and principal financial and accounting officer of the Company and entered into a Master Services Agreement (the “Consulting Agreement”) with Titan Advisory Services LLC for the provision of such principal financial and accounting officer services by Mr. Elmasri. Mr. Elmasri’s appointment to principal financial and accounting officer of the Company will be effective beginning November 17, 2025. Under the terms of the Consulting Agreement, the Company will pay Titan Advisory Services LLC $42,000 per year, or $3,500 per month, for services rendered by Mr. Elmasri as Chief Financial Officer. In addition, the Company shall grant, or the Company’s Chief Executive Officer, Lynn Stockwell, shall transfer 100,000 shares of the Company’s ordinary shares to Saleem Elmasri upon engagement.SIGNATURE

~~Mr.~~Pursuant to the requirements of ~~Elmasri’s~~the ~~biographical~~Securities ~~information~~Exchange isAct asof ~~follows:~~1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Mr. Elmasri~~Dated: isMarch a CPA and seasoned business professional with 20 years of experience in financial and management consulting. Mr. Elmasri began his career at PricewaterhouseCoopers(“PwC”) and worked on several of the firm’s Fortune 500 clients6, ~~primarily~~ focused on the Life Sciences and Pharmaceutical industry. From PwC, he transitioned to lead advisory practices at boutique consulting firms, specializing in transaction and complex accounting advisory.2026

~~From September~~DRUGS ~~2020~~MADE toIN ~~the~~AMERICA ~~present,~~ACQUISITION heII has served as the Managing Partner at Titan Advisory Services LLC, a boutique advisory firm focused on providing collaborative and customized financial operations and CFO services to early-stage companiesCORP. ~~From~~By: ~~June~~/s/ ~~2019~~Roger toBendelac ~~August~~Name: ~~2020, he~~Roger ~~was~~Bendelac ~~Managing~~Title: ~~Director~~Chief atExecutive DLA LLC. From March 2018 to June 2019, he worked as Senior Director for Pine Hill Group LLC, a boutique accounting and transaction advisory firm. From September 2007 to March 2018, Mr. Elmasri advanced through a series of progressively responsible roles, culminating in the position of Senior Manager for PricewaterhouseCoopers LLP, a Big-4 Accounting and Global Professional Services firm. Mr. Elmasri received B.S. degrees in Accounting and Finance from Rutgers University in 2007.Officer

In connection with his appointment, Mr. Elmasri is expected to enter into an Indemnity Agreement, a Letter Agreement and a Registration Rights Agreement with the Company on the same terms as the other directors and officers of the Company that executed similar agreements at the time of the consummation of the Company’s initial public offering. The Indemnity Agreement, Letter Agreement and Registration Rights Agreement will be in the forms of the agreement that are filed as exhibits to the Company’s Annual Report on Form 10-K, which was filed with the U.S. Securities and Exchange Commission. Other than the foregoing, Mr. Elmasri is not party to any arrangement or understanding with any person pursuant to which he was appointed as an executive officer of the Company, nor is he party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company. There are no family relationships between Mr. Elmasri and any of the Company’s directors and executive officers. 2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 17, 2025

DRUGS MADE IN AMERICA ACQUISITION II CORP. By: /s/ Lynn Stockwell Name: Lynn Stockwell Title: Chief Executive Officer

Filing Compare · Drugs Made In America Acquisition II Corp.